MARKET

RNAZ

RNAZ

TRANSCODE THERAPEUTICS INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.300
+0.270
+13.30%
After Hours: 2.300 0 0.00% 16:25 01/24 EST
OPEN
2.010
PREV CLOSE
2.030
HIGH
2.300
LOW
1.980
VOLUME
45.56K
TURNOVER
--
52 WEEK HIGH
7.00
52 WEEK LOW
1.952
MARKET CAP
29.68M
P/E (TTM)
-8.3273
1D
5D
1M
3M
1Y
5Y
TransCode Therapeutics To Participate at H.C. Wainwright BioConnect Conference
BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the H.C. Wainwright BioConnect Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe ...
GlobeNewswire · 01/06 20:17
TransCode Therapeutics To Participate at MedInvest Oncology Investor Conference
BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the MedInvest Oncology Investor Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe...
GlobeNewswire · 12/07/2021 00:10
Companies Like TransCode Therapeutics (NASDAQ:RNAZ) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Simply Wall St. · 11/18/2021 15:57
TransCode Therapeutics reports Q3 results
TransCode Therapeutics (NASDAQ:RNAZ): Q3 GAAP EPS of -$0.20. Press Release As of September 30, 2021, cash and cash equivalents totaled approximately $22.5M, largely reflecting the net proceeds from the July
Seekingalpha · 11/15/2021 21:50
BRIEF-TransCode Therapeutics Reports Q3 Loss Per Share $0.20
reuters.com · 11/15/2021 21:19
TransCode Therapeutics Q3 EPS $(0.20) Up From $(0.30) YoY
TransCode Therapeutics (NASDAQ:RNAZ) reported quarterly losses of $(0.20) per share. This is a 33.33 percent increase over losses of $(0.30) per share from the same period last year.
Benzinga · 11/15/2021 21:19
BRIEF-Transcode Therapeutics Appoints Zdravka Medarova As Chief Technology Officer
reuters.com · 09/30/2021 20:09
34 Stocks Moving In Friday's Mid-Day Session
Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares jumped 76.2% to $6.08.
Benzinga · 09/24/2021 16:06
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RNAZ. Analyze the recent business situations of TRANSCODE THERAPEUTICS INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
-0.55%
Key Executives
Independent Director
Magda Marquet, PhD
Independent Director
Erik Manting, PhD
Co-Founder, Scientific Advisor
Anna Moore, PhD
Co-Founder and Vice President Drug Discovery
Zdravka Medarova, PhD
Vice President of Operations
Judy Carmody, PhD
Chief Scientist
Qiyong Peter Liu, PhD
Independent Director, Chairman of the Board of Directors
Philippe P. Calais, PhD
Vice President, Chief Financial Officer, Director
Thomas A. Fitzgerald, MBA
Co-Founder, President, Chief Executive Officer, Director
Robert Michael Dudley
No Data
About RNAZ
TransCode Therapeutics, Inc. is a ribonucleic acid (RNA) oncology company. The Company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer. TTX-MC138 comprises proprietary iron-oxide nanoparticles and oligonucleotides that specifically target microRNA-10b. The nanoparticles serve as the vehicle to deliver oligonucleotides to metastatic cancer cells. The magnetic properties of these nanoparticles allow for monitoring of their delivery using non-invasive imaging. Its pipeline products also include TTX-siPDL1, TTX-siLIN28b and TTX-RIGA. TTX-siPDL1 is a checkpoint inhibitor targeting programmed cell death protein ligand 1 (PD-L1). TTX-RIGA utilizes its delivery system and is intended to activate the RIG-I signaling pathway to elicit an immune response to eliminate and/or reduce the risk of developing disorders associated with abnormal apoptotic or differentiative processes, by triggering an immune response that targets developing cancer cells.

Webull offers kinds of Transcode Therapeutics Inc stock information, including NASDAQ:RNAZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAZ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RNAZ stock methods without spending real money on the virtual paper trading platform.